Journal of Clinical Toxicology
Open Access
ISSN: 2161-0495
+44 1478 350008
ISSN: 2161-0495
+44 1478 350008
Fatemeh Namvaran
Posters: J Clinic Toxicol
A fter organ transplantation, an immunosuppressive drug FK506 (tacrolimus) which interrupts Ca-calmodulin?calcineurin signaling pathways in T lymphocytes by blocking antigen activation of T cell early activation genes, will be used. Among its side effects, tacrolimus can cause insulin-requiring diabetes mellitus during clinical use. In fact, it increases the risk of post- transplant diabetes (PTDM). The incidence of insulin-dependent PTDM was significantly higher among tacrolimus-treated patients than among cyclosporine-treated patients (9.8% vs. 2.7%). The purpose of this study was to evaluate the effects of FK506 on human beta cells. We measured the antioxidant status and reactive oxygen species (ROS) levels after tacrolimus treatment. The production of ROS was determined by the flow cytometry. Total antioxidant status (TAS) was measured using TAS kits. Tacrolimus resulted in dose- and time-dependent increases in the production of ROS by beta cells. The antioxidant status decreased in the beta cells after tacrolimus treatment. Increased production of ROS species and decreased antioxidant status by tacrolimus in beta cells may contribute to its side effects.
Fatemeh Namvaran has completed his Ph.D at the age of 30 years from Tehran University of Medical Sciences, College of Medicine. She is working with Transplant Research Center, Shiraz University of Medical Sciences. She has published 10 papers in reputed journals